Successful administration of venovenous extracorporeal membrane oxygenation through the modified Blalock–Taussig operation in an infant with graft dysfunction after the Norwood procedure

Megumi Kanao-Kanda
Takayuki Kunisawa
Kunihiko Yamamoto
Hirotsugu Kanda
Hiroshi Iwasaki

Department of Anesthesiology and
Critical Care Medicine, Asahikawa
Medical University, Asahikawa,
Hokkaido, Japan

Dear editor

Insufficient pulmonary blood flow through a right ventricle-to-pulmonary artery conduit following the Norwood procedure is remediable by adding a modified Blalock–Taussig shunt (MBTS).¹ First, however, perioperative hypoxemia must be managed. Venovenous extracorporeal membrane oxygenation (VV-ECMO) is likely to be a useful method for respiratory support in such cases.^{2,3} We present the case of a 2-month-old patient with graft dysfunction after the Norwood procedure who underwent MBTS with VV-ECMO support.

Case report

Due to graft dysfunction after the Norwood operation, a 2-month-old female infant (height 49 cm, weight 3.1 kg) was scheduled for an emergency right MBTS. VV-ECMO was also planned to avoid the risk of perioperative hypoxemia. After anesthetic induction, an 8 Fr bicaval dual-lumen catheter (GamCath® pediatric catheter; Gambro, Lund, Sweden) was placed in the right internal jugular vein under ultrasound guidance and VV-ECMO was implemented.^{4,5} Transesophageal echocardiography was used to evaluate the ventricular function and volume status, along with the hemodynamics. Upon initiation of VV-ECMO, the drainage flow volume temporarily decreased. A volume challenge was immediately performed with 5% albumin to achieve an appropriate preload. The hemodynamic responses were monitored by transesophageal echocardiography.⁶ The VV-ECMO circuit became stable after the volume load. The VV-ECMO flow rate was maintained at 150 mL/min, with the rotor at 3000 rpm. During right pulmonary artery clamping, the oxygen saturation improved to approximately 90%, with a pO_2 of 313 mmHg on a FiO_2 of 1. The MBTS was successfully performed. Subsequent VV-ECMO weaning was uneventful. VV-ECMO was finally withdrawn due to persistent stability of the patient's hemodynamic status.

Conclusion

VV-ECMO is an effective management strategy not only for adults but also for infants with refractory cardiorespiratory failure. Based on our experience with this patient,

Correspondence: Megumi Kanao-Kanda
Department of Anesthesiology and
Critical Care Medicine, Asahikawa
Medical University, Midorigaoka-higashi
2-1-1-I, Asahikawa, Hokkaido,
078-8510, Japan
Tel +81 166 68 2583
Fax +81 166 68 2589
Email megumikanao618@yahoo.co.jp

VV-ECMO provides useful respiratory support to avoid hypoxemia during MBTS operation in infants with graft dysfunction after the Norwood procedure.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Hsia T, Migliavacca F, Pennati G, et al. Management of a stenotic right ventricle-pulmonary artery shunt early after the Norwood procedure. *Ann Thorac Surg*. 2009;88(3):830–837.
2. Hayes D Jr, Galantowicz M, Yates AR, Preston TJ, Mansour HM, McConnell PI. Venovenous ECMO as a bridge to lung transplant and a protective strategy for subsequent primary graft dysfunction. *J Artif Organs*. 2013;16(3):382–385.
3. Mitchell MB, Campbell DN, Bielefeld MR, Doremus T. Utility of extracorporeal membrane oxygenation for early graft failure following heart transplantation in infancy. *J Heart Lung Transplant*. 2000;19(9):834–839.
4. Lazar DA, Cass DL, Olutoye OO, et al. Venovenous cannulation for extracorporeal membrane oxygenation using a bicaval dual-lumen catheter in neonates. *J Pediatr Surg*. 2012;47(2):430–434.
5. Hayes D Jr, McConnell PI, Preston TJ, Yates AR, Kirkby S, Galantowicz M. Active rehabilitation with venovenous extracorporeal membrane oxygenation as a bridge to lung transplantation in a pediatric patient. *World J Pediatr*. 2013;9(4):373–374.
6. Cavarocchi NC, Pitcher HT, Yang Q, et al. Weaning of extracorporeal membrane oxygenation using continuous hemodynamic transesophageal echocardiography. *J Thorac Cardiovasc Surg*. 2013;146(6):1474–1479.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Therapeutics and Clinical Risk Management 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Therapeutics and Clinical Risk Management editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Therapeutics and Clinical Risk Management

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS,

Submit your manuscript here: <http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>

EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress